As a partner in the Australian office of K&L Gates, Chris Round represents clients in copyright, trademark, patent,associated trade practices in Australian Courts.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced changes in its operating model for the Healthcare business sector. Chris Round will become President of EMD Serono leading the North America Healthcare business; Andrew Paterson will assume the position of Chief Marketing Officer; and recruitment is ongoing for the position of Head of China & International.
“Our redesigned Healthcare organization creates dedicated leadership for our strategic priorities with a focus on growth,” said Peter Guenter, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare. “Our clear intent is to bring meaningful value to more patients with our current and future portfolio.”
May 18, 2021 11:39am
Germany-based Merck KGaA saw an 8.6% increase in sales in 2020 and looks for even more success with reorganization of its healthcare unit in North America as it tries to spur sales of Mavenclad, Bavencio and Tepmetko. (Fierce Pharma)
Belen Garijo took over last month as CEO at Merck KGaA and she’s not wasting time putting her imprint on the company.
On Tuesday, the Germany-based company said it had tapped Chris Round as president at its North America healthcare unit, replacing Andrew Patterson, who ll step into the brand-new role of chief marketing officer.
By beefing up its leadership in the United States, Merck aims to help EMD Serono cash in with three promising drugs––its Pfizer-partnered immuno-oncology drug Bavencio, multiple sclerosis treatment Mavenclad and Tepmetko for non-small cell lung cancer.